Mcl-1
Showing 1 - 25 of >10,000
Myopia Trial in Singapore (Myopia Control Lens-1 (MCL1), Myopia Control Lens-2 (MCL2))
Not yet recruiting
- Myopia
- Myopia Control Lens-1 (MCL1)
- Myopia Control Lens-2 (MCL2)
-
Singapore, SingaporeEssilor R&D Centre Singapore
Nov 27, 2023
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma Trial in Worldwide (MIK665)
Completed
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
-
Houston, Texas
- +7 more
Jul 27, 2021
Acute Myeloid Leukaemia Trial in Australia, France, United States (S 64315 (also referred as MIK665) and venetoclax)
Terminated
- Acute Myeloid Leukaemia
- S 64315 (also referred as MIK665) and venetoclax
-
New Haven, Connecticut
- +6 more
Dec 20, 2022
Acute Myeloid Leukaemia Trial in Worldwide (S 64315 (also referred as MIK665) and azacitidine)
Active, not recruiting
- Acute Myeloid Leukaemia
- S 64315 (also referred as MIK665) and azacitidine
-
Houston, Texas
- +6 more
Dec 16, 2022
Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)
Recruiting
- Mantle Cell Lymphoma
- Refractory Lymphoma
- Acalabrutinib
- +2 more
-
Boston, Massachusetts
- +1 more
Aug 8, 2022
Mantle Cell Lymphoma (MCL) Trial in Australia, Canada, United States (Acalabrutinib, Venetoclax, Rituximab)
Not yet recruiting
- Mantle Cell Lymphoma (MCL)
- Acalabrutinib
- +2 more
-
Duarte, California
- +11 more
Jul 17, 2023
Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial
Not yet recruiting
- Aggressive B-Cell Non-Hodgkin's Lymphoma
- +4 more
- (no location specified)
Dec 16, 2022
Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease, Mantle Cell Lymphoma Trial in Poland (Acalabrutinib 2x100 MG
Recruiting
- Chronic Lymphocytic Leukemia
- +4 more
- Acalabrutinib 2x100 MG Oral Capsule + alloSCT
-
Warszawa, Mazowieckie, Poland
- +5 more
Dec 23, 2021
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS) Trial in Worldwide (S64315 once a week, S64315 twice a week)
Completed
- Acute Myeloid Leukaemia (AML)
- Myelodysplastic Syndrome (MDS)
- S64315 once a week
- S64315 twice a week
-
New Haven, Connecticut
- +8 more
May 17, 2022
Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)
Suspended
- Mantle Cell Lymphoma
- Acalabrutinib
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 7, 2022
Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)
Recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)
Recruiting
- CLL
- +9 more
- TG-1801
- Ublituximab
-
Fayetteville, Arkansas
- +4 more
Jan 20, 2023
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Eprenetapopt, Venetoclax)
Withdrawn
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
-
Houston, TexasM D Anderson Cancer Center
Feb 23, 2022
Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Tumor (SM-AHN), Mast Cell Leukemia (MCL) Trial in
Recruiting
- Advanced Systemic Mastocytosis (AdvSM)
- +3 more
- CGT9486 tablets
-
Duarte, California
- +10 more
Jul 8, 2022
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL) Trial in Manchester,
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- +7 more
-
Manchester, United Kingdom
- +2 more
Aug 11, 2022
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,
Active, not recruiting
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +9 more
- BTK inhibitor PCI-32765
- +5 more
-
Columbus, OhioOhio State University Medical Center
Jun 27, 2022
Acute Myeloid Leukemia Trial in Worldwide (Alvocidib, Cytarabine, Mitoxantrone)
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) Trial in United States (voruciclib
Recruiting
- Follicular Lymphoma (FL)
- +6 more
- voruciclib monotherapy
- voruciclib and venetoclax
-
Duarte, California
- +10 more
Aug 10, 2022
Diffuse Large B-cell Lymphoma(DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL) Trial in Worldwide (AMG 562)
Completed
- Diffuse Large B-cell Lymphoma(DLBCL)
- +2 more
- AMG 562
-
Duarte, California
- +11 more
Feb 22, 2022
Breast Cancer, HER2 Positive Trial in Netherlands (PTC+Pertuzumab, FEC-T+Pertuzumab)
Active, not recruiting
- Breast Cancer
- HER2 Positive
-
Alkmaar, Netherlands
- +32 more
Oct 11, 2022
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM) Trial in United States
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- +6 more
-
Duarte, California
- +10 more
Jul 14, 2022
CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)
Active, not recruiting
- CCND1 Positive
- +6 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 11, 2022